(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
Live Chart Being Loaded With Signals
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed...
Stats | |
---|---|
Today's Volume | 43 532.00 |
Average Volume | 46 044.00 |
Market Cap | 16.45B |
EPS | $0 ( 2024-03-19 ) |
Next earnings date | ( $0 ) 2024-05-14 |
Last Dividend | $0.247 ( 2023-05-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | 42.94 |
ATR14 | $0.0290 (0.40%) |
Volume Correlation
Fresenius SE & Co. KGaA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fresenius SE & Co. KGaA Correlation - Currency/Commodity
Fresenius SE & Co. KGaA Financials
Annual | 2023 |
Revenue: | $22.30B |
Gross Profit: | $5.06B (22.68 %) |
EPS: | $-1.050 |
Q4 | 2023 |
Revenue: | $5.68B |
Gross Profit: | $1.30B (22.84 %) |
EPS: | $-1.090 |
Q3 | 2023 |
Revenue: | $5.52B |
Gross Profit: | $1.27B (23.05 %) |
EPS: | $-0.730 |
Q2 | 2023 |
Revenue: | $10.36B |
Gross Profit: | $2.33B (22.52 %) |
EPS: | $0.140 |
Financial Reports:
No articles found.
Fresenius SE & Co. KGaA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.247 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.119 | 2013-05-15 |
Last Dividend | $0.247 | 2023-05-18 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-30 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $2.15 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.98 | -- |
Div. Sustainability Score | 7.07 | |
Div.Growth Potential Score | 2.08 | |
Div. Directional Score | 4.57 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PRNDY | Ex Dividend Knight | 2023-06-30 | Semi-Annually | 0 | 0.00% | |
EVSBY | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
UETMF | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
KNRRY | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
CIBN | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
SATLF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
FUPEF | Ex Dividend Knight | 2023-05-04 | Sporadic | 0 | 0.00% | |
ALBY | Ex Dividend Junior | 2023-05-30 | Sporadic | 0 | 0.00% | |
WLWHY | Ex Dividend Knight | 2023-09-21 | Annually | 0 | 0.00% | |
MHGVY | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0150 | 1.500 | -0.300 | -0.450 | [0 - 0.5] |
returnOnAssetsTTM | -0.0105 | 1.200 | -0.351 | -0.421 | [0 - 0.3] |
returnOnEquityTTM | -0.0240 | 1.500 | -1.377 | -2.07 | [0.1 - 1] |
payoutRatioTTM | -2.58 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 1.342 | 0.800 | 8.29 | 6.63 | [1 - 3] |
quickRatioTTM | 0.921 | 0.800 | 9.29 | 7.43 | [0.8 - 2.5] |
cashRatioTTM | 0.275 | 1.500 | 9.59 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.310 | -1.500 | 4.83 | -7.25 | [0 - 0.6] |
interestCoverageTTM | 2.67 | 1.000 | -0.121 | -0.121 | [3 - 30] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.48 | 2.00 | 7.26 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.739 | -1.500 | 7.04 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.233 | 1.000 | 9.45 | 9.45 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0585 | 1.000 | -0.829 | -0.829 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.317 | 1.000 | 9.35 | 9.35 | [0.2 - 2] |
assetTurnoverTTM | 0.702 | 0.800 | 8.65 | 6.92 | [0.5 - 2] |
Total Score | 7.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.50 | 1.000 | -0.859 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0240 | 2.50 | -0.885 | -2.07 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.48 | 2.00 | 8.17 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.89 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
payoutRatioTTM | -2.58 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | -0.0162 | 1.500 | -3.44 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.140 | 1.000 | 8.99 | 0 | [0.1 - 0.5] |
Total Score | 2.08 |
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators